This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Peptron Co., Ltd.. Active years: 2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2015
Title: Innovations of Joon-Sik Kim in Controlled-Release Technology
Introduction
Joon-Sik Kim is a notable inventor based in Daejeon, South Korea. He has made significant contributions to the field of controlled-release drug delivery systems. His innovative work focuses on enhancing the bioavailability and effectiveness of therapeutic agents.
Latest Patents
One of Joon-Sik Kim's key patents is titled "Composition and microsphere for controlled-release of exendin, and method preparing the same." This patent describes a controlled-release composition that includes exendin as an active ingredient, combined with a biodegradable polymer and specific coating materials. The invention aims to provide sustained release of the active ingredient without an excessive initial burst, ensuring effective concentration over time. The method of preparing these controlled-release microspheres involves mixing exendin, a biodegradable polymer, and a solvent, followed by the removal of the solvent to create hardened microspheres.
Career Highlights
Joon-Sik Kim is associated with Peptron Co., Ltd., where he continues to advance research in drug delivery systems. His work has garnered attention for its potential applications in improving patient outcomes through more effective medication delivery.
Collaborations
Throughout his career, Joon-Sik Kim has collaborated with talented individuals such as Mi-Young Baek and Ho-Il Choi. These collaborations have contributed to the development of innovative solutions in the pharmaceutical field.
Conclusion
Joon-Sik Kim's contributions to controlled-release technology exemplify the importance of innovation in the pharmaceutical industry. His work not only enhances drug delivery systems but also paves the way for future advancements in medical treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile